Compare Fubotv Inc (FUBO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Recursion Pharmaceuticals Inc — how do they compare? Fubotv Inc trades at $10.24 (market cap $302.39M), while Recursion Pharmaceuticals Inc trades at $3.06 (market cap $1.75B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 5.8× Fubotv Inc's market cap. Which is the better fit depends on your goals.
| FUBO | RXRX | |
|---|---|---|
Market Cap | $302.39M | $1.75B |
Sector | Technology | Health |
52-Week High | $54.72 | $6.79 |
52-Week Low | $8.09 | $2.84 |
Enterprise Value | $472.81M | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO stock trades at $10.46, up 9.64% on the day, with a bullish technical signal and strong analyst support. The company shows improving fundamentals, with revenue reaching $1.62B in 2024 and a projected net profit of $123M in 2025. Recent CEO appointment of former Disney+ executive Alisa Bowen has driven positive sentiment, while valuation ratios like P/E of 2.67 and P/S of 0.21 appear attractive relative to historical norms.
The outlook for FUBO is cautiously optimistic, with upside to the $16.25 consensus price target, but risks include persistent cash flow challenges and intense streaming competition. Investors should weigh the potential for profitability growth against execution risks in a crowded market.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
